Quick10K

⚲

Emmaus Life Sciences

Filings

10-Q	2019-03-31	Filed 2019-05-14
10-K	2018-12-31	Filed 2019-03-21
10-Q	2018-09-30	Filed 2018-11-14
10-Q	2018-06-30	Filed 2018-08-14
10-Q	2018-03-31	Filed 2018-05-15
10-K	2017-12-31	Filed 2018-04-16
10-Q	2017-09-30	Filed 2017-11-14
10-Q	2017-06-30	Filed 2017-08-21
10-Q	2017-03-31	Filed 2017-05-12
10-K	2016-12-31	Filed 2017-03-31
10-Q	2016-09-30	Filed 2016-11-14
10-Q	2016-06-30	Filed 2016-08-19
10-Q	2016-03-31	Filed 2016-06-06
10-K	2015-12-31	Filed 2016-05-20
10-K	2015-09-30	Filed 2016-05-20
10-Q	2015-06-30	Filed 2016-05-20
10-Q	2015-03-31	Filed 2015-05-20
10-K	2014-12-31	Filed 2015-03-31
10-Q	2014-09-30	Filed 2014-11-13
10-Q	2014-06-30	Filed 2014-08-14
10-Q	2014-03-31	Filed 2014-05-20
10-K	2013-12-31	Filed 2014-05-08
10-Q	2013-09-30	Filed 2013-11-14
10-Q	2013-06-30	Filed 2013-08-14
10-Q	2013-03-31	Filed 2013-05-15
10-K	2012-12-31	Filed 2013-03-29
10-Q	2012-09-30	Filed 2012-11-14
10-Q	2012-06-30	Filed 2012-08-14
10-Q	2012-03-31	Filed 2012-05-14
10-K	2011-12-31	Filed 2012-03-30
10-Q	2011-09-30	Filed 2011-11-14
10-Q	2011-06-30	Filed 2011-08-15
10-Q	2011-04-30	Filed 2011-05-13
10-Q	2011-01-31	Filed 2011-03-11
10-K	2010-10-31	Filed 2011-01-31
10-Q	2010-07-31	Filed 2010-09-14
10-Q	2010-04-30	Filed 2010-06-14
10-Q	2010-01-31	Filed 2010-03-17
10-K	2009-10-31	Filed 2010-01-29

Reports

8-K	2019-07-09	Other Events, Exhibits
8-K	2019-07-08	Other Events, Exhibits
8-K	2019-07-03	Other Events, Exhibits
8-K	2019-06-12	Other Events, Exhibits
8-K	2019-05-29	Officers, Other Events, Exhibits
8-K	2019-03-05	Enter Agreement, Off-BS Arrangement, Other Events, Exhibits
8-K	2019-01-04	Enter Agreement, Regulation FD, Exhibits
8-K	2018-12-19	Amend Bylaw, Exhibits
8-K	2018-10-09	Enter Agreement
8-K	2018-09-27	Officers, Shareholder Vote
8-K	2018-09-13	Enter Agreement, Sale of Shares, Exhibits
8-K	2018-07-16	Officers
8-K	2018-06-13	Officers
8-K	2018-03-29	Enter Agreement, Exhibits
8-K	2018-01-30	Enter Agreement
8-K	2017-12-29	Leave Agreement, Exhibits

Emmaus Life Sciences Financials

EMMA Metrics, Comps, Filings

Quarterly | Annual

Business

In this discussion, the terms, "we," "us," "our" or the "Company" refer to Emmaus Life Sciences, Inc., and its direct and indirect wholly‑owned subsidiaries.

On January 7, 2019, we announced our entry into an Agreement and Plan of Merger and Reorganization, dated as of January 4, 2019 (as it may be amended, the "MYnd Merger Agreement"), among Emmaus, MYnd Analytics, Inc. ("Parent" or "MYnd") and Athena Merger Subsidiary, Inc. ("Merger Sub"), pursuant to which Merger Sub will merge (the "Merger") with and into Emmaus, with Emmaus surviving as a subsidiary of Parent. For a discussion of risks and uncertainties relating to the Merger, see "Risk Factors - Risks Relating to the Proposed Merger" in this Annual Report.

We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases and a leader in the treatment of sickle cell disease, or SCD. On July 7, 2017, the U.S. Food and Drug Administration, or FDA, approved our lead product, Endari™ (L-glutamine oral powder), to reduce the acute complications of SCD in adult and pediatric patients five years of age and older.

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin


Comps ($'000 TTM)	Market Cap	Gross Margin	EV/EBITDA	Ret on Assets	Assets	Liabilities	Revenue	G Profit	Net Income	EBITDA	EV
First Northern Community Bancorp (FNRN)	136,114		0.0	1%	1,287,263	1,157,741	0	0	11,145	16,699	21
JRSIS Health Care (JRSS)	135,419	0%	23.1	5%	53,817	29,543	22,907	0	2,913	5,783	133,410
magicJack VocalTec (CALL)	135,362	64%	5.6	5%	144,276	95,065	80,267	51,525	6,495	13,150	73,254
Federal Street Acquisition (FSAC)	135,270		-26.8	-1%	471,272	25,787	0	0	-3,966	-4,930	132,081
Invesco DB Precious Metals Fund (DBP)	133,440		10.1	10%	133,936	3,438	0	0	13,252	13,252	133,440
Bright Mountain Media (BMTM)	132,589	27%	-40.9	-12%	28,364	7,229	3,915	1,041	-3,451	-3,224	132,001
Living 3D (LTDH)	131,496	-27%	-587.9	-294%	80	957	36	-10	-236	-224	131,491
Darkpulse (KLMK)	130,846		-596.4	-114%	576	3,218	0	0	-659	-221	131,978
Invesco CurrencyShares Canadian Dollar Trust (FXC)	129,195	0%	-23.9	1%	115,580	40	1,541	0	993	993	-23,705
Gastar Exploration (GST)	129,171	0%	-45.1	-24%	335,253	447,533	82,913	0	-81,839	-10,744	484,737
Contango Ore (CTGO)	128,732		-16.5	-96%	7,639	407	0	0	-7,322	-7,322	121,121
Emmaus Life Sciences (EMMA)	128,334	96%	-5.7	-66%	70,735	95,363	12,760	12,198	-46,927	-28,944	165,192
RenovaCare (RCAR)	126,661		-51.9	-16%	13,627	483	0	0	-2,183	-2,183	113,287
WMIH (WMIH)	126,089	0%	-1.9	-2%	18,478,000	16,711,000	1,519,000	0	-325,000	267,000	-515,911
Coastway Bancorp (CWAY)	122,160		6.2	0%	834,904	761,474	0	0	3,067	11,692	72,076
SteadyMed (STDY)	121,680	0%	-6.0	-61%	27,830	23,512	430	0	-16,924	-16,656	100,551
Amplify Energy (AMPY)	121,564	0%	2.7	9%	722,684	317,597	285,911	0	63,813	101,197	277,537
Axcella Health (AXLA)	121,267		-1.0	-40%	109,187	34,843	0	0	-43,324	-42,806	41,912
Mobiquity Technologies (MOBQ)	121,110	42%	-3.5	-192%	18,378	5,177	6,647	2,816	-35,292	-34,760	120,580
ENB Financial (ENBP)	120,929		9.2	1%	1,145,998	1,030,361	0	0	10,841	17,453	159,728


Balance Sheet ($'000)	2011-06-30	2011-09-30	2011-12-31	2012-03-31	2012-06-30	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31
Cash	432	603	314	162	398	334	403	137	543	5,773	3,639	1,535	3,605	1,641	556	328	1,581	483	472	324	323	6,628	1,317	3,545	5,088	4,415	22,556	5,113	2,169	16,662	17,080	15,310
Accounts Receivable	39	78	18	76	43	52	80	44	45	25	35	27	65	54	43	15	21	23	102	61	54	20	14	27	11	10	27	685	1,702	1,415	1,351	1,760
Inventory	282	234	195	215	240	256	203	165	162	168	239	253	259	224	250	268	223	295	219	302	242	252	166	261	271	396	625	1,008	2,435	3,347	4,705	5,795
PP&E	83	78	60	55	192	195	196	196	197	201	204	225	227	229	265	267	267	270	270	271	274	275	281	326	359	361	361	376	414	441	454	456
Assets	3,677	3,216	2,482	4,172	3,315	3,084	2,884	3,093	3,793	9,034	6,114	3,616	5,820	3,658	2,664	2,207	3,447	2,284	1,477	1,345	1,263	21,562	12,993	15,386	48,424	33,604	123,845	113,502	73,935	84,806	74,555	70,735
Accounts Payable					1,351	1,658	1,758	1,967	1,493	1,324	836	914	594	655	1,218	1,752	454	1,187	1,524	1,470	1,745	1,339	476	952	888	1,272	1,600	1,790	2,986	2,646	3,604	5,186
Long-Term Debt					8,147	9,432	11,305	12,414	11,493	11,499	11,467	11,555	13,137	11,723	11,986	13,079	17,420	17,715	19,128	18,899	20,680	18,073	16,696	18,880	19,949	24,309	48,724	40,402	40,319	49,993	55,172	52,168
Liabilities	3,712	4,637	5,457	8,431	10,715	12,444	13,527	15,341	13,877	16,305	19,951	22,863	25,258	23,616	22,964	24,323	25,994	27,313	30,040	31,696	32,937	30,846	30,554	36,967	76,171	89,490	109,555	101,986	103,223	96,351	90,449	95,363
Stockholders' Equity	-35	-1,422	-2,975	-4,260	-7,400	-9,360	-10,643	-12,248	-10,084	-7,271	-13,838	-19,247	-19,438	-19,958	-20,300	-22,116	-22,547	-25,030	-28,563	-30,351	-31,674	-9,284	-17,562	-21,581	-27,748	-55,885	14,291	11,516	-29,289	-11,545	-15,797	-24,546


Income Statement ($'000)	2011-06-30	2011-09-30	2011-12-31	2012-03-31	2012-06-30	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31
Revenue	98	152	28	145	107	113	178	90	91	66	144	85	126	156	153	97	144	77	272	79	173	62	148	107	164	140	147	781	2,571	4,882		5,307
Cost of Revenue	46	57	4	21	29	37	97	44	62	48	49	47	61	90	69	50	64	37	136	28	83	21	89	48	73	129	62	135	221	141		200
Gross Profit	52	95	24	125	108	77	80	46	36	18	95	38	67	65	84	47	81	40	136	51	90	41	59	59	92	12	85	647	2,350	4,741		5,107
R&D	338	533	371	543	896	780	757	615	696	490	635	605	711	507	257	244	303	465	567	502	585	369	532	756	1,584	379	483	411	396	466		513
SG&A	1,653	2,219	1,023	1,635	2,671	1,878	2,526	2,534	3,399	2,721	2,598	3,112	3,781	2,874	3,197	3,372	2,447	2,252		2,387	2,341	2,760	2,294	2,901	3,747	3,438	6,362	4,677	4,711	6,406		5,166
Tax	0	0	3	6	0	0	1	3	2	0	-185	2	2	0	1	2	2	0		2	0	0	1	2	0	0	1			0
Net Income	-1,947	-2,913	-2,841	-2,945	-4,195	-3,452	-3,842	-3,363	-3,662	-3,708	-3,245	-6,740	-7,378	-3,726	-2,972	-3,604	-1,655	-3,444		-4,460	-3,142	-6,258	-7,318	-6,495	-11,776	-17,267	2,166	-6,097	-47,343	14,569		-14,153


Cash Flow ($'000)	2011-06-30	2011-09-30	2011-12-31	2012-03-31	2012-06-30	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31
Cash Operating		-2,450	-1,505	-1,014	-1,794	-1,613	-2,028	-1,436	-2,339	-1,937	-2,677	-2,172	-2,876	-2,218	-1,469	-1,228		-1,235	-1,486	-2,360	-2,071	-15,415	9,813	1,966	579	-5,913	27,563	-615		-1,665		-1,284
Cash Investing		-1	1	-1,502	-3	-2	0	0	-1	-4	588	-21	-2	-2	-38	-1						0	-14,008	-40	-44	-2	-31,974	-484		6,380		-16
Cash Financing		2,622	1,218	2,367	2,068	1,553	2,069	1,176	2,770	7,178	-65	88	4,948	260	425	1,002		126	1,431	2,208	2,067	21,650	-1,031	299	968	5,234	22,616	-16,330		9,775		-492